Bifogade filer
Kurs
-35,83%
Likviditet
1,02 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-20 | 07:30 | Bokslutskommuniké 2025 |
2025-11-07 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-21 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-28 | N/A | X-dag ordinarie utdelning PLUN 0.00 SEK |
2025-05-27 | N/A | Årsstämma |
2025-05-16 | 07:30 | Kvartalsrapport 2025-Q1 |
2025-02-20 | - | Bokslutskommuniké 2024 |
2024-12-23 | - | Split PLUN 40:1 |
2024-12-05 | - | Extra Bolagsstämma 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-19 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2024-05-30 | - | Årsstämma |
2024-05-16 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-07 | - | Kvartalsrapport 2023-Q3 |
2023-10-12 | - | Extra Bolagsstämma 2023 |
2023-07-14 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | Kvartalsrapport 2023-Q1 |
2023-05-05 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-10-21 | - | Kvartalsrapport 2022-Q3 |
2022-07-14 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-05-05 | - | Kvartalsrapport 2022-Q1 |
2022-02-18 | - | Bokslutskommuniké 2021 |
2021-10-22 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2021-05-11 | - | Årsstämma |
2021-05-07 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Bokslutskommuniké 2020 |
2020-10-23 | - | Kvartalsrapport 2020-Q3 |
2020-08-21 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-21 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Årsstämma |
2019-05-08 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2019-04-16 | - | Årsstämma |
2019-04-16 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-11-14 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-05-17 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2018-05-16 | - | Årsstämma |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-05-10 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2017-05-09 | - | Årsstämma |
2017-05-09 | - | Kvartalsrapport 2017-Q1 |
2017-02-23 | - | Bokslutskommuniké 2016 |
2016-11-10 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-18 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2016-05-17 | - | Årsstämma |
2016-05-17 | - | Kvartalsrapport 2016-Q1 |
2016-02-26 | - | Bokslutskommuniké 2015 |
2015-11-13 | - | Kvartalsrapport 2015-Q3 |
2015-08-28 | - | Kvartalsrapport 2015-Q2 |
2015-05-12 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2015-05-11 | - | Årsstämma |
2015-05-11 | - | Kvartalsrapport 2015-Q1 |
2015-02-27 | - | Bokslutskommuniké 2014 |
2014-11-28 | - | Kvartalsrapport 2014-Q3 |
2014-08-29 | - | Kvartalsrapport 2014-Q2 |
2014-05-14 | - | Kvartalsrapport 2014-Q1 |
2014-05-06 | - | X-dag ordinarie utdelning PLUN 0.00 SEK |
2014-05-05 | - | Årsstämma |
2014-02-22 | - | Bokslutskommuniké 2013 |
2013-11-20 | - | Kvartalsrapport 2013-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
- Fourth quarter in a row with growth
1 Januay-31 March
- Net sales reached SEK 5,6 (4,6) million
- Loss after taxes SEK -3,2 (-2,1) million
- Earnings per share were SEK -0,06 SEK (-0,04)
- Cash and equivalents were 6,3 (7,9) million
Significant events during period
- CE-mark for the new platform Eagle obtained
- Patent that include the Schelin Catheter is approved
- An agreement with a new clinic in Stockholm was signed
- An agreement with a new clinic in Karlshamn was signed
- Agreement with SLG Kalmar is signed with an order value of SEK 2,4 million
Significant events after the end of the period
- Distribution agreement for Poland was signed
- Schelin Catheter® approved for sale in the province of Hainan in China
- The board decided on May 17th 2023 to carry out a rights issue of approx. 40 MSEK before issue costs
Key figures | ||||
(SEK MILLION) | jan-mar 2023 | jan-mar 2022 | jan-mar 2021 | jan-mar 2020 |
Net sales | 5,6 | 4,6 | 5,3 | 4,6 |
Gross margin, % | 68 | 81 | 83 | 72 |
Operating profit/loss | -3,2 | -2,1 | -1,2 | -1,6 |
Cash flow from operating activities | -5,5 | -5,1 | -2,2 | 1,4 |
Average number of employees | 9 | 7 | 7 | 5 |
”The first quarter of the year was characterized by the same intensity as 2022. We began the year with continued growth and reported the highest turnover ever during a quarter”
Johan Wennerholm
CEO, ProstaLund AB (publ)
Please see attached PDF for full report.
For further information, please contact:
Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com
About ProstaLund
ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.
Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se
This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-17 08:15 CEST.